Professional Documents
Culture Documents
Panoura 18S: 1-3-6, Kotobashi, Sumida-Ku
Panoura 18S: 1-3-6, Kotobashi, Sumida-Ku
Michizo Yamanaka
President
IContact person
Hidenori Watanabe
International Regulatory Affairs
Phone: 011-81- 3-3631-2165
Fax: 011-81- 3-3633-9420
Email: hi-watanabe~yoshida-net.cojp
b. Contact/Application Correspondent
Fumiaki Kanai, Ph.D.
President and CEO
MIC International
4-1-17 Blongo, Bunkyo-ku
Tokyo, 113-0033, Japan
Phone: 011-81-3-3818-8577
Fax: 011-81-3-3818-8573
Email: kanaif@mici.cojp
c. Date prepared
April 29, 2011
d. Name of device
Trade Name: PANOURA 188
Common Name: Extraoral source x-ray system
Classification Name: System, x-ray, extracral source, digital
Classification Regulation: 21 CER 872.1800
e. Predicate devices
The PANOURA 18S is substantially equivalent to the following legally marketed device:
510(k): K093683
Trade name: ORTHOPANTOMOGRAPH 0P300
Product code: MUR
* Intended use
* Operational characteristics
* Ionizing radiation
* Cephalometric radiogram
* Panoramic images by producing conventional 2D X-ray images as well as X-ray
projection images
Difference regarding intended use between the PANO1JRA 18S and the
ORTHOPANTOMOGRAPH (k093683) is that the ORTH-OPANTOMOGRAPH (k093683) has
following additional intended use compared to the PANOUR A 18S:
those testing and analysis demonstrated that the PANOURA I 8S did not raise any new safety
or effectiveness concerns compared to the ORTHOPANTOMOGRAPH (k093683)
i. Comparison table
Table 6-1 compares the characteristics between the PANOURA I18S and the
ORTHOPANTOMOGRAPH (k093683).
-pl
'IT'
-4 t
4) >
~~tr
Ct~~ r > 4 o
oo.
ZO~ O CtR0
eq 79 En
u .5)2c M
N ~ ~ ' tS
0C U
A - m
-d -
0 0u
Cz
0s 0,
0 0 0
' CQ
CZ
C/)O CZ~
14 - -L
CD4
tb
z
00
0.000.0
- u
PANOURA I18S
PREMARKET NOTIFICATION 5 10(k)
62304 LEG Medical device software - Software life cycle processes 2006
14971 IOMedical devices - Application of risk management to medical 2007
_________ __ ____ ___ devices
k. Conclusion
The PANOURA 18S has the same intended use except regarding computerized tomography
and reconstructed 3-D image and similar operational and technological characteristics as the
ORTHOPANTOMOORAPH (k093683). The performance test results indicate that the PANOURA
18S meets the requirements of recognized consensus or voluntary standard. Based on the
information presented above regarding substantial equivalence to the
ORTHOPANTOMOORAPH (k093683), THE YOSIDA DENTAL MFG. Co., LTD. concludes that the
PANOURA 18S is substantially equivalent to the ORTEOPANTOMOORAPH (k093683) and does
not raise any new questions regarding safety or effectiveness.
Re: K1112313
Trade/Device Name: Panoura 18S 2A
Regulation Number: 21 CFR 872.1800
Regulation Name: Extraoral source x-ray system
Regulatory Class: 11
Product Code: MUH
Dated: April 29, 2011
Received: May 2, 2011
We have reviewed your Section 5 10(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into class 11 (Special Controls), it may be subject to such
additional controls. Existing major regulations affecting your device can be found in Title 21,
Code of Federal Regulations (CER), Parts 800 to 895. In addition, FDA may publish further
announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act's requirements, including, but not limited to: registration and listing'(21
CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
Page 2
medical device-related adverse events) (21 CFR 803); and good manufacturing practice
requirements as set forth in the quiality systems (QS) regulation (21 CER Part 820). This letter
will allow you to begin marketing your device as described in your Section 5 10(k) premarket
notification. The FDA finding of substantial equivalence of your device to a legally marketed
predicate device results in a classification for your device and thus, permits your device to
proceed to the market.
If you desire specific advice for- your device on our labeling regulation (21 CFR Parts 801 and
809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-
5450. Also, please note the regulation entitled, "Misbranding by reference to premarket
notification" (21 CER Part 807.97). For questions regarding the reporting of adverse events
under the MDR regulation (21 CFR Part 803), please go to
http://w-ww-A.fda.g~ov/MedicalDevices/Safety/Repoi-taproblem/default.htm for the Office
-LRHs
of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on youir responsibilities under the Act from thle
Division of Small Manufacturers, International and Consumer Assistance at its toll-free number
(800) 6389-2041 or (301) 796-7100 dr at its Internet address
http://www.fda. gov/cdrlindustry/support/index.htrnl.
Sincerely Yours,
Enclosure
Indications for Use
ionign-off)o
510K